Patents Assigned to Nippon Shinyaku Co., Ltd.
  • Patent number: 10780087
    Abstract: A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: September 22, 2020
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventors: Shouji Furuta, Hironori Mukai
  • Patent number: 10781448
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 22, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
  • Publication number: 20200223823
    Abstract: A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”). A Form-I crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2?: 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu K? radiation (?=1.54 ?). A Form-II crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2?: 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu K? radiation (?=1.
    Type: Application
    Filed: September 27, 2018
    Publication date: July 16, 2020
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventors: Toshio FUJIWARA, Joanna BIS, Senthil Kumar Kusalakumari SUKUMAR
  • Publication number: 20200223804
    Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2?) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?). A form-III crystal of Compound B, which shows peaks at diffraction angles (2?) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?).
    Type: Application
    Filed: September 27, 2018
    Publication date: July 16, 2020
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventor: Toshio FUJIWARA
  • Patent number: 10683322
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 16, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Patent number: 10662217
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: May 26, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Publication number: 20200149040
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: June 11, 2019
    Publication date: May 14, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Patent number: 10647741
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: May 12, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Publication number: 20200123546
    Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., Kawasaki Gakuen Educational Foundation
    Inventor: Shinichiro NAKAGAWA
  • Publication number: 20200115411
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: May 10, 2019
    Publication date: April 16, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Publication number: 20200109162
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 9, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Publication number: 20200102343
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 2, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Patent number: 10563199
    Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: February 18, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., KAWASAKI GAKUEN EDUCATIONAL FOUNDATION
    Inventors: Shinichiro Nakagawa, Seigo Nagata, Yoshihide Sunada, Yutaka Ohsawa, Shin-ichiro Nishimatsu
  • Patent number: 10487106
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 26, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Publication number: 20190315796
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 17, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Patent number: 10407461
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: September 10, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Patent number: 10385092
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 20, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Publication number: 20190218244
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Publication number: 20190211050
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: March 26, 2019
    Publication date: July 11, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Publication number: 20190211049
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: March 20, 2019
    Publication date: July 11, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA